Live
Novo NordiskNovo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - simplywall.stEurofinsEurofins Scientific SE Stock (FR0014000MR3): stock in focus after quiet trading week - AD HOC NEWSCellMechanism of lipid transfer by bridge-like protein VPS13A and the scramblase XKCellGregory J. Hannon (1964–2026)FierceBiotechLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’Eli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - investor.lilly.comEli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - PR NewswireEli LillyLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ - Fierce BiotechEli LillyAbridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion - Healthcare DiveEndpoints NewsBiopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and moreClinical OMICsLong-Read DNA Test Could Replace 15 Existing Tests for Rare Diseases10x Genomics Blog10x Genomics (TXG) Stock Valuation After Recent Surge In Returns - simplywall.st
FierceBiotech 12. Feb. 2026

Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval

Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.